Drug maker stays close to doctors and patients
New York Times, March 17, 2008
Peter A. Kouides, MD, a hematologist at Rochester (NY) General Hospital, said he once had a patient with Gaucher disease who declined to be treated with a drug made by Genzyme. For years, Genzyme's representatives were always asking the hospital about why they were not treating the patient, he says. While most pharmaceutical makers do not even know the identities of most of the people taking their drugs, Genzyme knows virtually everyone with Gaucher disease. As a result, some critics say Genzyme influences treatment to an unusual extent and encourages the use of high doses of its drug.
Most Viewed
Most Emailed
- $6.4B Henry Ford, Beaumont Merger Failed on Cultural Hurdles
- Don't Let Nurses Sink Your Bottom Line
- Fortunately, Angelina Jolie Isn't On Medicare
- Hospitals Profit On Bloodstream Infections
- Less Blood Testing for Some Surgeries Safe, Cost Effective
- How Chargemaster Data May Affect Hospital Revenue
- Primary Care Docs Average More Hospital Revenue Than Specialists
- House Lawmakers Grill CMS Over Health Exchange Navigators
- Lower ED Margins Demand a Better Strategy
- ED Physicians Key to Half of Hospital Admissions
